Author: Vidal-Cortés, Pablo; del RÃo-Carbajo, Lorena; Olmo, Jorge Nieto-del; Prol-Silva, EstefanÃa; Tizón-Varela, Ana I.; RodrÃguez-Vázquez, Ana; RodrÃguez-RodrÃguez, Pilar; DÃaz-López, MarÃa D.; Fernández-Ugidos, Paula; Pérez-Veloso, Marcos A.
Title: COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome Cord-id: 4e8xwr75 Document date: 2020_12_15
ID: 4e8xwr75
Snippet: OBJECTIVES: To assess the impact of corticosteroids on inflammatory and respiratory parameters of patients with COVID-19 and acute respiratory distress syndrome (ARDS). METHODS: Longitudinal, retrospective, observational study conducted in an ICU of a second level hospital. Adult patients with COVID-19 were included. Baseline characteristics, data on SARS-CoV-2 infection, treatment received, evolution of respiratory and inflammatory parameters, and ICU and hospital stay and mortality were analyz
Document: OBJECTIVES: To assess the impact of corticosteroids on inflammatory and respiratory parameters of patients with COVID-19 and acute respiratory distress syndrome (ARDS). METHODS: Longitudinal, retrospective, observational study conducted in an ICU of a second level hospital. Adult patients with COVID-19 were included. Baseline characteristics, data on SARS-CoV-2 infection, treatment received, evolution of respiratory and inflammatory parameters, and ICU and hospital stay and mortality were analyzed. RESULTS: A total of 27 patients were included, 63% men, median age: 68.4 (51.8, 72.2) years. All patients met ARDS criteria and received MV and corticosteroids. After corticosteroids treatment we observed a reduction in the O(2) A-a gradient [day 0: 322 (249, 425); day 3: 169 (129.5, 239.5) p<0.001; day 5: 144 (127.5, 228.0) p<0.001; day 7: 192 (120, 261) p=0.002] and an increase in the pO(2)/FiO(2) ratio on days 3 and 5, but not on day 7 [day 0: 129 (100, 168); day 3: 193 (140, 236) p=0.002; day 5: 183 (141, 255) p=0.004; day 7: 170 (116, 251) p=0.057]. CRP also decreased on days 3 and 5 and increased again on day 7 [day 0: 16 (8.6, 24); day 3: 3.4 (1.7, 10.2) p<0.001; day 5: 4.1 (1.4, 10.2) p<0.001; day 7: 13.5 (6.8, 17.3) p=0.063]. Persistence of moderate ARDS on day 7 was related to a greater risk of poor outcome (OR 6.417 [1.091-37.735], p=0.040) CONCLUSION: Corticosteroids appears to reduce the inflammation and temporarily improve the oxygenation in COVID-19 and ARDS patients. Persistence of ARDS after 7 days treatment is a predictor of poor outcome.
Search related documents:
Co phrase search for related documents- absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absence presence and lopinavir ritonavir: 1, 2
- absence presence and low mortality: 1, 2, 3, 4
- absence presence and lymphocyte count: 1, 2, 3, 4, 5, 6
- active search and logistic regression: 1, 2
- active search and lopinavir ritonavir: 1
- admission present and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- admission present and lopinavir ritonavir: 1, 2, 3, 4
- admission present and low lymphocyte count: 1
- admission present and low mortality: 1, 2, 3
- admission present and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
- admission present and lymphocyte count ferritin: 1
- liver renal failure and logistic regression: 1, 2, 3
- liver renal failure and lopinavir ritonavir: 1, 2
- liver renal failure and low mortality: 1
- liver renal failure and lymphocyte count: 1
- logistic regression and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- logistic regression and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- logistic regression and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date